MD, PhD Malene Grubbe Hildebrandt Department of Nuclear Medicine, Odense University Hospital
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Inkluderede deltagere med prøver
Significance of follow-up FDG-PET / CT for patients on adjuvant immunotherapy with high-risk melanoma - SOFAIM
This study is designed to evaluate the efficacy of the current follow-up programme regarding FDG-PET/CT scans of patients treated with adjuvant immunotherapy following radical resection of high risk melanoma.
Since the fall of 2018, Danish patients with high-risk melanoma have been offered adjuvant immunotherapy after radical surgery, in order to reduce the risk of recurring disease. The patients who opt for the adjuvant immunotherapy are enrolled in an follow-up programme which consists of control scans 4 times during the first year after surgery. We seek to evaluate the diagnostic validity of these scans.
Description of the cohort
Patients with high-risk melanoma (IIb+c, III or IV), recieving immunotherapy after radical surgery, treated at OUH, Denmark.
Data and biological material
Pathology data provided initial diagnosis and staging, as well as recurrent disease diagnosis.
Patient record data:
Patient records from OUH provided data on the number of treatments patients recieved, scan-results, reasons for stopping treatment and outcome.
Danish Melanoma Database provided data on patients with the relevant diagnosis and stage of disease.
Collaborating researchers and departments
Department of Nuclear Medicine, Odense University Hospital
Stud. Med. Jesper Alexander Sommer Andersen
Stud. Med. Anders Dyhr Spatzek
MD, Associate Professor Peter Grupe
MD, Mie Vilstrup
Department of Oncology, Odense University Hospital